Full Text View
Tabular View
No Study Results Posted
Related Studies
Alternate Day Buprenorphine Administration, Phase XII - 17
This study has been completed.
Study NCT00000235   Information provided by National Institute on Drug Abuse (NIDA)
First Received: September 20, 1999   Last Updated: August 16, 2005   History of Changes

September 20, 1999
August 16, 2005
 
 
  • Drug use
  • Opioid withdrawal
  • Opioid agonist effects
  • Dose choice
Same as current
Complete list of historical versions of study NCT00000235 on ClinicalTrials.gov Archive Site
 
 
 
Alternate Day Buprenorphine Administration, Phase XII - 17
Alternate Day Buprenorphine Administration, Phase XII

The purpose of this study is to determine if six times daily buprenorphine dose is effective in achieving 120 hour buprenorphine dosing.

 
Phase II
Interventional
Treatment, Placebo Control, Crossover Assignment
Opioid-Related Disorders
Drug: Buprenorphine
 
 

*   Includes publications given by the data provider as well as publications identified by National Clinical Trials Identifier (NCT ID) in Medline.
 
Completed
0
 
 

Please contact site for information.

Both
18 Years and older
No
Contact information is only displayed when the study is recruiting subjects
United States
 
NCT00000235
 
NIDA-06969-17, R01-06969-17
National Institute on Drug Abuse (NIDA)
University of Vermont
Principal Investigator: Warren Bickel, Ph.D. University of Vermont
National Institute on Drug Abuse (NIDA)
December 2002

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP